Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives

por Seitzer, Konstantin Egon, Seifert, Robert, Kessel, Katharina, Roll, Wolfgang, Schlack, Katrin, Boegemann, Martin, Rahbar, Kambiz
Publicado 2021

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy

por Seifert, Robert, Seitzer, Konstantin, Herrmann, Ken, Kessel, Katharina, Schäfers, Michael, Kleesiek, Jens, Weckesser, Matthias, Boegemann, Martin, Rahbar, Kambiz
Publicado 2020

Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy

por Seifert, Robert, Kessel, Katharina, Schlack, Katrin, Weckesser, Matthias, Kersting, David, Seitzer, Konstantin E., Weber, Manuel, Bögemann, Martin, Rahbar, Kambiz
Publicado 2021

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

por Schlack, Katrin, Seitzer, Konstantin, Wüstmann, Neele, Humberg, Verena, Grundmann, Norbert, Steinestel, Julie, Tiedje, Dorothee, Rahbar, Kambiz, Krabbe, Laura-Maria, Bögemann, Martin, Schrader, Andres J., Bernemann, Christof
Publicado 2022

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer

por Wüstmann, Neele, Seitzer, Konstantin, Humberg, Verena, Vieler, Julia, Grundmann, Norbert, Steinestel, Julie, Tiedje, Dorothee, Duensing, Stefan, Krabbe, Laura-Maria, Bögemann, Martin, Schrader, Andres Jan, Bernemann, Christof, Schlack, Katrin
Publicado 2023